Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takara Bio to End License Deal for Oncolytic Viral Immunotherapy with Chinese Firm
August 6, 2020
- Sumitomo Dainippon, Save Medical Link Up on Diabetes App; Approval Eyed in FY2022
August 6, 2020
- LTL Pharma to Take Over Sanofi’s Dellegra in Japan
August 5, 2020
- Astellas’ Q1 Sales Falter 8% on Deal Terminations, COVID-19
August 5, 2020
- Celltrion Poised to Roll Out 20 Biosimilars in Japan over Next 10 Years
August 5, 2020
- Povidone-Iodine Gargle Meds Fly Off Pharmacy Shelves after Osaka COVID-19 Data
August 5, 2020
- First Patient Enrolled in Clinical Trial to Test 3 Drugs for COVID-19: AbbVie, Amgen, Takeda
August 5, 2020
- Mitsubishi Tanabe’s Sales Drop 6.5% in Q1, 5 Billion Yen Loss on Price Cuts
August 5, 2020
- PeptiDream, RayzeBio Tie Up on Peptide-Radiotherapeutics
August 5, 2020
- 4 More Products Recalled over Flawed Testing at Kyowa CritiCare
August 4, 2020
- Kyorin Out-Licenses Hearing Loss Med to Otonomy
August 4, 2020
- Paper Maker Oji Ventures into Pharma Biz with Wood-Derived Drugs, Eyes Clinical Trial by 2023
August 4, 2020
- Eisai Shakes Off Price Cut, Coronavirus Blow with Lenvima Growth in Q1
August 4, 2020
- 2 Astellas Sales Reps Infected with Novel Coronavirus
August 4, 2020
- Daiichi Sankyo to Curb Shipments for Herceptin Biosimilar on Surging Demand
August 4, 2020
- Opdivo-Avastin Combo Hits Goal in Non-Squamous NSCLC; Ono Prepping for Japan Filing
August 4, 2020
- Takeda to Merge Shire Japan in October
August 4, 2020
- JCR to Start Global Study of MPS I Med; Japan Launch Planned in September
August 4, 2020
- JCR to Boost Manufacturing Capacity for Temcell by 30%
August 4, 2020
- BMS Japan to Integrate Celgene Next Year, HQ Relocation Planned in H1 2022: Chief
August 3, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…